Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 8,223 shares, a decrease of 51.5% from the August 31st total of 16,949 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 27,409 shares, the days-to-cover ratio is presently 0.3 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded Elutia from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
View Our Latest Research Report on ELUT
Elutia Stock Performance
Elutia (NASDAQ:ELUT – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $2.43 million during the quarter, compared to analysts’ expectations of $2.90 million. Elutia had a negative return on equity of 407.37% and a net margin of 426.93%.
Hedge Funds Weigh In On Elutia
A number of institutional investors have recently bought and sold shares of ELUT. Rossmore Private Capital grew its holdings in Elutia by 140.0% during the first quarter. Rossmore Private Capital now owns 120,000 shares of the company’s stock valued at $126,000 after purchasing an additional 70,000 shares during the period. Knollwood Investment Advisory LLC raised its stake in shares of Elutia by 147.8% in the fourth quarter. Knollwood Investment Advisory LLC now owns 2,556,724 shares of the company’s stock worth $1,771,000 after buying an additional 1,525,157 shares during the period. Finally, AIGH Capital Management LLC lifted its position in shares of Elutia by 17.2% during the 1st quarter. AIGH Capital Management LLC now owns 3,595,250 shares of the company’s stock valued at $3,775,000 after buying an additional 527,065 shares in the last quarter. 74.03% of the stock is owned by institutional investors.
Elutia Company Profile
Elutia Inc (NASDAQ: ELUT) is a medical technology company focused on developing and commercializing biologic and drug-eluting products for regenerative medicine and implantable medical devices. Its technologies are designed to support tissue healing, improve the performance of implanted devices and address clinical needs in areas including cardiac care and orthopedics.
The company’s product portfolio has included the CanGaroo family of biologic envelopes, which are used to help manage and protect implantable electronic devices such as pacemakers and defibrillators.
Further Reading
- Five stocks we like better than Elutia
- Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks
- Micron’s Earnings Reveal Why the AI Memory Boom May Last Longer
- Hobby Boom or Travel Bust? Here Are 3 Stocks to Ride the Trend
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
